TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial

For patients with locally recurrent rectal cancer (LRRC), the response rate to chemoradiotherapy is 40%–50%. Additionally, only approximately 40%–50% of patients with recurrent rectal cancer are able to undergo R0 resection. Recent studies in locally advanced rectal cancer (LARC) have shown promisin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Juefeng, Wu, Ruiyan, Fu, Miaomiao, Shen, Lijun, Zhang, Hui, Wang, Yan, Wang, Yaqi, Zhou, Shujuan, Chen, Yajie, Xia, Fan, Zhang, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694348/
http://dx.doi.org/10.3389/fonc.2023.1304767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694348/
http://dx.doi.org/10.3389/fonc.2023.1304767

Ejemplares similares